Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 259

The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.

Epidemiology of Thyroid Cancer

Open access
Kitahara, Cari M., Schneider, Arthur B.·2022·Cancer Epidemiology, Biomarkers & Prevention

Abstract

The incidence of thyroid cancer has risen dramatically in the United States over the past four decades, with similar patterns observed internationally. Thyroid cancer currently ranks as the 13th most common cancer diagnosis overall and the 6th most common among women. Because the greatest increases in incidence have been observed for small and localized tumors having the highest rate of survival, the incidence trends have been primarily attributed to overdiagnosis, resulting from more widespread use of diagnostic imaging and more sensitive diagnostic tools. Increasing incidence of large and advanced thyroid cancers, as well as thyroid cancer mortality, suggests that etiologic factors may have contributed to rising incidence of the disease, albeit to a lesser extent than overdiagnosis. Until recently, childhood exposure to ionizing radiation was considered the only established modifiable risk factor for thyroid cancer. Obesity has emerged as another important risk factor, although the underlying biological mechanisms remain poorly understood. The potential influence of endocrine-disrupting chemicals and thyroid dysfunction on thyroid cancer development has been a focus of recent etiologic studies. Important recent advances in identifying molecular subtypes of thyroid cancer and genetic susceptibility factors provide insights regarding the etiology of this disease.Of the major histologic types, about 90% are papillary thyroid carcinomas (PTC), 4% follicular thyroid carcinomas (FTC), 2% Hürthle cell carcinomas, 2% medullary thyroid carcinomas (MTC), and 1% anaplastic thyroid carcinomas (ATC; ref. 1). MTCs are neuroendocrine tumors arising from calcitonin-producing C cells (parafollicular cells). Other rare thyroid cancers, with some exceptions (e.g., squamous cell, lymphoma, mesenchymal tumors), arise from follicular cells.Thyroid cancers are also classified according to genetic drivers. The 2014 Cancer Genome Atlas Research Network landmark publication reported work that led to the identification of driver mutations in over 95% of nearly 500 PTCs (2). Subsequent work using a similar approach has identified Hürthle cell thyroid cancers as a separate entity from PTCs and FTCs (3). PTCs can now be distinguished according to those with somatic mutations related to the BRAF mutations in the MAPK pathway (BRAF-like) and those related to RAS mutations (RAS-like). BRAFV600E mutation has been associated with disease recurrence and mortality in patients with PTC, particularly when co-occurring with TERT promotor mutations (4, 5). BRAF and RAS mutations appear to play an important role in the development of poorly differentiated and anaplastic thyroid cancers, with BRAFV600E being an early molecular event and TP53 mutations contributing to the progression of PTCs to poorly differentiated and anaplastic types (5). TP53 mutations are present in about 26% of poorly differentiated cancers and 80% of ATCs, but rarely occur in PTCs (5). In general, the TERT promotor mutation and TP53 mutation, especially if co-occurring or co-occurring with other mutations, are strongly linked to higher degrees of dedifferentiation, disease aggressiveness, and poor outcomes (5). RET/PTC rearrangements are another distinct and common molecular event in the development of PTC; these occur more frequently in individuals exposed to radiation in childhood where they act through the MAPK pathway (ref. 6; see the "Ionizing radiation" section). RET mutations are the most common somatic mutations in MTCs, following by H-RAS and K-RAS (5).Thyroid cancer incidence varies substantially by geographic location (Fig. 1A), especially in women (7). In general, the highest incidence is observed in higher-income countries, including the Republic of Korea, Canada, Italy, France, Israel, Croatia, Austria, and the United States, as well as some middle- to upper–middle-income countries, such as Turkey, Brazil, Costa Rica, and China (7, 8). Incidence is also high in some island nations and territories, including Cyprus, Cabo Verde, French Polynesia, New Caledonia, and Puerto Rico (7). This variation is thought to be mainly attributable to geographic differences in access to care and diagnostic practices, although environmental exposures may also play a role (9). Compared with incidence, thyroid cancer mortality rates tend to be much lower and vary much less geographically (Fig. 1B).In the United States, thyroid cancer is estimated to be the 13th most commonly diagnosed cancer, accounting for nearly 44,000 new cancer diagnoses in 2022 (2.3% of the total), and the 6th most commonly diagnosed cancer among women (10). Thyroid cancer incidence is approximately 3-fold higher in women (22.8 per 100,000 per year in 2014–2018) than in men (8.0 per 100,000 per year; Fig. 2A; ref. 1). Thyroid cancer incidence increases from adolescence through middle age, peaking around 55 years in women and 65 years in men, and subsequently declining with older age (Fig. 2B; ref. 11). Current

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-21-1440

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 156 references

Metadata

Authors
Kitahara, C. M., & Schneider, A. B.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2022-07-01
Volume
31
Issue
7
Pages
1284-1297
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W4283742900
Cited by
259
References
156
FWCI
31.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology of Thyroid Cancer. https://app.cochat.ai/papers/10.1158/1055-9965.epi-21-1440
The paper
Kitahara, C. M., & Schneider, A. B. (2022). Epidemiology of Thyroid Cancer. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-21-1440

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.